Nonalcoholic Fatty Liver Disease
Conditions
Brief summary
Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases. Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD. This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD.
Detailed description
Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases. Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. In a large cross-sectional study, the researcher were the first to confirm that serum uric acid level was significantly increased in patients with NAFLD. The results were published in J Hepatol. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD. This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD.
Interventions
DRUGfebuxostat treatment
According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
BEHAVIORALlifestyle intervention
According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Sponsors
Ningbo No. 1 Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A total of 200 subjects are enrolled in this study. After the initial screening, the subjects were randomly divided into the control group and the drug treatment group. The control group was given lifestyle intervention at 0-24 weeks, and the experimental group was given febuxostat oral therapy on the basis of lifestyle intervention. If the results showed that the reduction of liver fat content of subjects in the lifestyle intervention combined with febuxostat treatment group was significantly better than that in the lifestyle intervention group alone, the original intervention was continued in the drug treatment group, and the control group was given febuxostat orally on the basis of the lifestyle intervention at 24-48 weeks.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* with informed consent; * Ages 18-65; * Overweight/obesity: BMI ≥24kg/m2; * A history of gout with serum uric acid levels of \> 420μmol/L in men and postmenopausal women, and \>360 μmol/L in premenopausal women; * Moderate or above fatty liver was found in the initial screening by ultrasound, and the liver fat content was more than 15% as determined by MRI-PDFF.
Exclusion criteria
* with a history of allergy to febuxostat and allopurinol; * in the acute active phase of gout; * Drinking equivalent to alcohol intake ≥30g/d(male), ≥20g/d(female); * Patients with obvious abnormal liver function: serum transaminase (ALT, AST, GGT one of them) or serum bilirubin (direct bilirubin, indirect bilirubin one of them) exceed 2 times the upper limit of normal reference value; Serum albumin \<35g/L; * Have a history of viral hepatitis, or serological examination suggests hepatitis virus infection, or have a history of other liver diseases; * Complicated with renal insufficiency (SCr \>133μmol/L) or urinary protein +; * Complicated coronary heart disease; * Cardiac dysfunction (cardiac function grade 2 or above); * Complementation with diabetes, or fasting blood glucose \>7.8mmol/L, or HbA1c \>7.5%; * Severe hypertension, blood pressure ≥ 160/100 mmHg; * Patients with asthma and other respiratory diseases; * Intestinal diseases such as inflammatory bowel disease; * Any history of systemic malignancy in the past 5 years; * Morbid obesity (BMI\>37.5kg/m2); * Triglyceride ≥5.0 mmol/L was found to be significantly abnormal in baseline examination; * had received systemic hormone or immunosuppressive therapy within 3 months prior to screening, or expected to receive hormone or immunosuppressive therapy in the future; * Use of uric-lowering drugs in the 4 weeks before screening: febuxostat, benzobromarone, allopurinol; * Use of other drugs affecting uric acid metabolism were adjusted within 4 weeks before screening: losartan, fenofibrate, irbesartan, thiazide diuretics, loop medullaral diuretics, compound antihypertensive agents containing diuretics; * Other drugs that may affect liver fat content were taken within 4 weeks before screening; * Weight change ≥5% within 3 months before screening; * Women who are lactating or pregnant or who plan to become pregnant within one year; * were enrolled in other studies within 6 months before screening; * unsuitable for participants to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum uric acid levels of subjects in different groups | at the first week | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
| Liver fat content of subjects in different groups | at the first week. | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). |
Countries
China
Outcome results
None listed